Latest Commercial Deployment News

Australian Vanadium reported progress across its mine, electrolyte and battery businesses, but auditors highlighted material uncertainty over the company’s ability to continue as a going concern. The group held $17.9 million in cash at 30 June, yet expects to need additional funding within 12 months.

Alfabs Australia’s FY26 reset preserved free cash flow despite a sharp earnings decline, while Mining growth and debt refinancing form the bridge to a potential dividend restart. The company enters FY27 leaner, but the plan still depends on execution, cash conversion and Phase II debt restructuring.

Dataworks Group delivered a much-improved FY26, with revenue up 24%, operating cash flow turning positive and its Ontario platform entering commercial operation. But the ASX-listed regtech company remains loss-making, carries net liabilities of $1.93 million and says its survival depends on further funding.

4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.

Simble Solutions is extending its NanoSensor technology into terrestrial solar monitoring, using its existing SimbleSense and CarbonView platforms as a potential route to commercialisation. The opportunity remains at the benchmark-testing stage, with space-based solar identified as a longer-term possibility rather than an immediate product or revenue stream.

FBR has opened a fully underwritten A$2.5 million share purchase plan to fund testing and commercialisation of its Mantis and Hadrian robotics platforms. Eligible shareholders can subscribe at the lower of A$0.115 or a discounted five-day VWAP, with one five-year option attached to each share issued.

Adisyn says the USPTO has allowed its third US patent application, extending its graphene deposition claims from metallic surfaces to non-metallic semiconductor materials. The allowed claims also include low-temperature processing and in-process quality checks, although commercial adoption remains unconfirmed.

Iondrive Limited’s updated evaluation of its IONSolv™ technology projects a US$243 million post-tax NPV and US$62 million annual EBITDA for a single rare earth recovery module in the US, driven by high feedstock grade assumptions and independently validated recoveries.

Phoslock Environmental Technologies has advanced a new range of lanthanum-enhanced phosphorus-binding products showing up to four times the capacity of current offerings, with pilot and manufacturing tests confirming strong performance and low lanthanum release. Field trials are underway, aiming for commercial sales in 2027.

Vitrafy Life Sciences has secured its first US cell and gene therapy foothold by deploying its cryopreservation technology at Charter Medical's Innovation Hub, signalling a strategic expansion into a high-value biopharma segment.

Anson Resources has lodged two US patent applications for a novel chemical-free technology that removes iron from lithium-rich brines, potentially cutting costs and environmental impact in its Direct Lithium Extraction process.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.